Increased Expression of Fatty-Acid and Calcium Metabolism Genes in Failing Human Heart

Vanessa García-Rúa1, Manuel Francisco Otero1,3, Pamela Virginia Lear1, Diego Rodríguez-Penas1, Sandra Feijóo-Bandín1, Teresa Noguera-Moreno5, Manuel Calaza2, María Álvarez-Barredo4, Ana Mosquera-Leal1, John Parrington6, Josep Brugada7, Manuel Portolés8, Miguel Rivera8, José Ramón González-Juanatey1,4, Francisca Lago1

1 Laboratory of Cellular and Molecular Cardiology, Santiago Institute of Biomedical Research (IDIS), University of Santiago de Compostela Clinical Hospital (CHUS), Santiago de Compostela, Spain, 2 Laboratory 10, Santiago Institute of Biomedical Research (IDIS), University of Santiago de Compostela Clinical Hospital (CHUS), Santiago de Compostela, Spain, 3 Department of Clinical Chemistry, University of Santiago de Compostela Clinical Hospital (CHUS), Santiago de Compostela, Spain, 4 Department of Cardiology, University of Santiago de Compostela Clinical Hospital (CHUS), Santiago de Compostela, Spain, 5 Unit of Biostatistical Research, University of Santiago de Compostela, Santiago de Compostela, Spain, 6 Department of Pharmacology, Oxford University, Oxford, United Kingdom, 7 Cardiology Department, Thorax Institute, Hospital Clinic, Barcelona, Spain, 8 La Fe University Hospital, Valencia, Spain

Abstract

Background: Heart failure (HF) involves alterations in metabolism, but little is known about cardiomyopathy-(CM)-specific or diabetes-independent alterations in gene expression of proteins involved in fatty-acid (FA) uptake and oxidation or in calcium-(Ca2+)-handling in the human heart.

Methods: RT-qPCR was used to quantify mRNA expression and immunoblotting to confirm protein expression in left-ventricular myocardium from patients with HF (n = 36) without diabetes mellitus of ischaemic (ICM, n = 16) or dilated (DCM, n = 20) cardiomyopathy aetiology, and non-diseased donors (CTL, n = 6).

Results: Significant increases in mRNA of genes regulating FA uptake (CD36) and intracellular transport (Heart-FA-Binding Protein (HFABP)) were observed in HF patients vs CTL. Significance was maintained in DCM and confirmed at protein level, but not in ICM. mRNA was higher in DCM than ICM for peroxisome-proliferator-activated-receptor-alpha (PPARA), PPAR-gamma coactivator-1-alpha (PGC1A) and CD36, and confirmed at the protein level for PPARA and CD36. Transcript and protein expression of Ca2+–handling genes (Two-Pore-Channel 1 (TPCN1), Two-Pore-Channel 2 (TPCN2), and Inositol 1,4,5-triphosphate Receptor type-1 (IP3R)) increased in HF patients relative to CTL. Increases remained significant for TPCN2 in all groups but for TPCN1 only in DCM. There were correlations between FA metabolism and Ca2+–handling genes expression. In ICM there were six correlations, all distinct from those found in CTL. In DCM there were also six (all also different from those found in CTL): three were common to and three distinct from ICM.

Conclusion: DCM-specific increases were found in expression of several genes that regulate FA metabolism, which might help in the design of aetiology-specific metabolic therapies in HF. Ca2+–handling genes TPCN1 and TPCN2 also showed increased expression in HF, while HF- and CM-specific positive correlations were found among several FA and Ca2+–handling genes.

Introduction

Human heart failure (HF) has been described as a hyperadrenergic state leading to increased plasma levels of free fatty acids (FFA), which in turn cause a range of metabolic dysfunctions including aberrant FA uptake and oxidation in the myocardium [1]. Therapeutic modulation of FA metabolism [1,2], stimulation of glucose metabolism [3] and selective targeting of sarcolemmal transporters of FA or glucose, depending on presence or absence of diabetes [4] are all currently under consideration. The putatively adaptive switch from predominantly FA to predominantly glucose oxidation via the Randle cycle during progression to myocardial failure has received increasing attention [3,5–7].
However, mechanisms linking alterations in FA uptake and oxidation per se with HF in humans, particularly in relation to aetiology and treatment, remain poorly understood.

One consistent finding in HF patients is an increase in plasma levels of Heart Fatty-Acid-Binding Protein (HFABP) which can be substantial [9–10]. In light of its role in intracellular transport to the mitochondria where FAs undergo β-oxidation [11], it is of note that expression levels of HFABP within the myocardium have not previously been studied in HF patients. Potential alterations in human HF between cardiac HFABP and its downstream enzymes of FA oxidation are thus unknown. An important regulator of HFABP and several subsequent steps in FA utilisation, peroxisome-proliferator-activated-receptor-alpha (PPARA) [12,13], has also been found to have altered expression in human HF [14–16].

HF-related changes in myocardial gene expression have also been found at various points in the FA uptake and oxidation pathways in humans and animal models for the following genes: Cluster-of-Differentiation 36 (CD36, also known as Fatty-Acid Translocase (FAT) and an important FA transporter across the plasma and outer mitochondrial membranes) [5,17]; Cardiac Carnitine Palmitoyl-Transferase-1 (CPT-1, the other principal outer mitochondrial membrane FA transporter) [15,18,19]; and Long-Chain Acyl-CoA Dehydrogenase (LCAD, a key enzyme of β-oxidation) [18,20–22].

PPARA and LCAD are also known to be regulated by PPAR-gamma coactivator-1-alpha (PGC1A) [23], while altered mitochondrial function has been associated with excess levels of plasma FFA in HF patients [24], and in rodent models with excess FA levels not only in plasma but also within the cardiomyocyte [25–27]. However, many discrepancies still exist in the findings of studies on alterations in the FA uptake-oxidation pathway as a whole in human HF. This is probably due to HF having been viewed as a single pathological end-point, rather than as different aetiology-specific diseases [28,29].

Aberrant lipid metabolism can also disrupt intracellular calcium (Ca²⁺) homeostasis – specifically Ca²⁺ cycling and inositol-3-phosphate receptors (IP₃Rs) levels – and cause endoplasmic reticulum (ER) stress [30–33], one of whose main markers is known to be the protein CHOP (CCAAT/enhancer-binding-protein-homology protein) [34,35]. Altered expression of IP₃Rs has previously been identified in cardiac hypertrophy patients [36]. The two-pore channels TPCN1 and 2 have been recently identified as a novel class of endo-lysosomal Ca²⁺ channels and likely receptors for NAADP, nicotinic acid adenine dinucleotide phosphate, the most potent Ca²⁺ mobilizing messenger known [37,38,39].

Our purpose was to look for changes in the expression of proteins involved in FA uptake and oxidation or in Ca²⁺-handling in the failing human heart, with the aim of defining aetiology-specific diseases [28,29]. Aberrant lipid metabolism can also disrupt intracellular calcium (Ca²⁺) homeostasis – specifically Ca²⁺ cycling and inositol-3-phosphate receptors (IP₃Rs) levels – and cause endoplasmic reticulum (ER) stress [30–33], one of whose main markers is known to be the protein CHOP (CCAAT/enhancer-binding-protein-homology protein) [34,35]. Altered expression of IP₃Rs has previously been identified in cardiac hypertrophy patients [36]. The two-pore channels TPCN1 and 2 have been recently identified as a novel class of endo-lysosomal Ca²⁺ channels and likely receptors for NAADP, nicotinic acid adenine dinucleotide phosphate, the most potent Ca²⁺ mobilizing messenger known [37,38,39].

Our purpose was to look for changes in the expression of proteins involved in FA uptake and oxidation or in Ca²⁺-handling in the failing human heart, with the aim of defining aetiology-specific differences between ischaemic and dilated heart failure patients.

Materials and Methods

Tissue Samples, and Demographic and Clinical Parameters

Transmurral left-ventricular myocardial biopsies were obtained from explanted human hearts from 16 patients with ICM and 20 patients with DCM, all without diabetes mellitus, in end-stage HF and undergoing heart transplantation, as previously described [40,41]. Cardiomyopathy groups were defined according to the following clinical criteria: ICM: LVEF <40% with coronary artery damage on angiogram (the majority having suffered a previous MI); DCM: LVEF <40% with intact coronary arteries, no previous MI, and dilated non-hypertrophic left ventricle on echocardiography (LVDD >55 mm [40,41]; Table 1). Non-diseased donor hearts in cardioplegic arrest for a mean time of two and a half hours, deemed unsuitable for transplant due to blood-type or size incompatibility, were used to obtain control myocardial tissue (CTL, n = 6; Table 2). The atrial tissue necessary for the standardization of some of the antibodies used in Western blot was obtained as pieces of right atrial appendage excised to allow catheterisation of the right atrium during surgery requiring cardiopulmonary bypass (tissue which is usually discarded).

All tissues were obtained with signed informed consent of patients. The project was approved by the local Ethics Committee (Biomedical Investigation Ethics Committee) and conducted in accordance with the guidelines of the Declaration of Helsinki.

Real-time PCR

RNA was extracted using a NucleoSpin kit, according to the manufacturer’s instructions (Macherey-Nagel, Germany). For relative quantification we performed a reverse-transcription reaction with 1 μg of RNA using a First Strand kit (Superarray Bioscience Corp, MD, USA). RNA quality and quantity was determined using a NanoDrop (Thermo Scientific, Spain) spectrophotometer. Next, a real-time PCR reaction was performed using the Superarray master mix provided, and 1 μl of cDNA in each well, for the following specific human primers: TPCN1: 86 bp, PPH00150E reference position 1287–1310 GenBank; TPCN2: 124 bp, PPH00150E reference position 1550 RefSeq Accession: NM_139075.3; GAPDH: 175 bp, PPH00150E reference position 1287–1310 GenBank; TPCN2: 124 bp, PPH00150E reference position 1550 RefSeq Accession: NM_139075.3. Amplification conditions were: 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 60 s. All Superarray primers were pre-optimised by the manufacturer.

A real-time PCR reaction was performed using the Solaris qPCR Gene Expression Master Mix with LOW ROX premixed, and 1 μl of total cDNA in each well, for the following specific human primers: GAPDH: GCCCTCAAGATCATCAGGAATG (forward) and CCTCCAGATACAGAAGTGGTG (reverse), Probe (GCGAACGTCACTCATGA), RefSeq Accession NM_002046.3; IP3R1: TGGGGCACACACTTCTAC (forward) and CTTTTGATATGCGCGGCA (reverse), Probe (AT-}

Table 1. Patient characteristics according to heart failure aetiology.

| Parameter         | ICM (n = 16) | DCM (n = 20) |
|-------------------|--------------|--------------|
| Age (yr), mean±SD | 53.6±8.1     | 46.5±11      |
| Gender male, n (%)| 16 (100)     | 17 (85)      |
| NYHA class (1–4), mean±SD | 3.6±1.0   | 3.4±0.5      |
| BMI (kg/m²), mean±SD | 25.5±4.0   | 25.1±4.6     |
| LVEF (%), mean±SD   | 23.2±5.6     | 19.6±7.6     |
| LVESD (mm), mean±SD  | 53.4±7.4     | 69.8±9.4     |
| LVEDD (mm), mean±SD  | 61.7±7.3     | 78.3±8.8     |
| LV mass (g), mean±SD | 258.7±54.2  | 390.8±116.4  |
| Duration of disease (m), mean±SD | 37.8±46.4 | 69.5±52.6 |

Duration of disease: from diagnosis to heart transplant; BMI: body mass index; DCM: dilated cardiomyopathy; ICM: ischaemic cardiomyopathy; LVEF: left ventricular ejection fraction; EDD: end diastolic diameter; ESD: end systolic diameter; NYHA: New York Heart Association. doi:10.1371/journal.pone.0037505.0001
TAGCCCATCAGTTGGC, RefSeq Accession NM_002222; NM_001099952; PPARA: CGAGTATTTAGGAAAGCTGCT (forward) and TGAAGCTGTGTCGCTGAT (reverse); Probe (CTCAGATGGCTCCGTCA), RefSeq Accession NM_032644; PGCIα: AATTGAGAGCGCCGCTGT (forward) and AAXCA-TAGCTGTTCCTCACA (reverse); Probe (AGTAAATCTGCGG-GAG), RefSeq Accession NM_013261; CPT1B: ACTGCTA-CAACAGGTTGTT (forward) and TC1GATTGAGACACAGCACTG (reverse); Probe (ATTTCCCTCAGAATCTG), RefSeq Accession NM_152247; NM_152248; CD36: GTTGCCGATAATGACAC (forward) and GCAGT-GACTTCCAAATGAG (reverse); Probe (GGTAAAGAAGGTT (reverse), RefSeq Accession NM_001001548; NM_001001547; NM_001001546; NM_001127444 and LCAD: CTTCCACAG-GAAGGCTGTT (forward) and CTTGGAAGATGGTCA (reverse), RefSeq Accession NM_001608.

Using primers designed with the Beacon Designer program (v3.1, Premier Biosoft International, CA, USA) and pre-optimised conditions, we also performed one-step real-time PCR with the Brilliant II SYBR Green QRT-PCR Master Mix Kit (Stratagene, CA, USA) and the same quantity of total RNA in each well (5 ng), for the following specific human primers: CHOP: CAGAAACAGCATACCTATG (forward) and CTCGTAATTTATITTTGTG-CACTG (reverse); Probe (GTGTCGCCTACCTACAGACAGT), RefSeq Accession NM_0010608. Using primers designed with the Beacon Designer program (v3.1, Premier Biosoft International, CA, USA) and pre-optimised conditions, we also performed one-step real-time PCR with the Brilliant II SYBR Green QRT-PCR Master Mix Kit (Stratagene, CA, USA) and the same quantity of total RNA in each well (5 ng), for the following specific human primers: CHOP: CAGAAACAGCATACCTATG (forward) and CTCGTAATTTATITTTGTG-CACTG (reverse); Probe (GTGTCGCCTACCTACAGACAGT), RefSeq Accession NM_0010608.

Individual genes showing HF- and CM-related changes in expression at the RNA level (HFABP, TPCN1, TPCN2, PPARA, IP3R1, CD36) were then tested at the protein level by immunoblotting. Tissue was lysed with Triton X-100 (1% v/v) buffered in 50 mmol/L Tris-HCl, 150 mmol/L NaCl, 5 mmol/L EDTA, 1 mmol/L phenylmethylsulfonylfluoride, 10 μg/ml leupeptin, 10 μg/ml aprotinin, 1 μg/ml trypsin inhibitor and 1 mmol/L Na3VO4). Samples were subjected to SDS-PAGE under denaturing conditions on 8% (TPCN1, TPCN2), 15% (HFABP), 10% (PPARA, CD36) and 4–20% (IP3R1) acrylamide gels and electroblotted onto PVDF membranes (Amersham Pharmacia Biotech, Germany). Membranes were treated with the following primary antisera, either at room temperature for 2 h (anti-PPARA, TPCN1, TPCN2) or at 4°C overnight (HFABP, CD36): HFABP: 1:1000; Santa Cruz Biotechnology, CA, USA; anti-CD36: 1:1000; Pierce Biotechnology-Thermo Scientific, IL, USA; anti-TPCN1 (1:1000) affinity-purified using a standard kit according to the manufacturer’s protocol (SulfoLink, Thermo Scientific UK) from rabbit anti-serum raised against specific TPCN1 antigenic human C-peptides; anti-TPCN2 (1:100; Novus Biologicals, CO, USA); anti-IP3R: 1:1000; Pierce Biotechnology-Thermo Scientific, IL, USA; and anti-IP3R. Membranes were then incubated with horseradish-peroxidase-conjugated secondary antibody (1:2000; Santa Cruz Biotechnology, CA, USA) and subjected to chemiluminescence detection (Millipore Corporate, MA, USA). Anti-GAPDH (1:1000; Santa Cruz Biotechnology, CA, USA) was used as a loading control. Densitometric analyses were performed using a UVP EC3 Imaging System (Ultra-Violet Products Ltd, UK) and the Image J program (v1.43 e; Rasband 1997–2008). N-Glycosidase F (PNGase F) Pre-treatment for Identification of TPCN1 and TPCN2 Protein Bands in Western Blot

Ours is the first report that includes the identification by western blot of the protein bands corresponding to TPCN1 and TPCN2 in human myocardium. In order to standardize a protocol for the identification of both proteins in human cardiac tissue, and having into account that in other tissues TPCN1 and TPCN2 are known to be N-glycosylated [42,43], we first performed several experiments that helped us to identify both proteins in our western blots. Briefly, and as described previously for HEK 293 cells [42,43], atrial protein (extract supernatant containing 20 μg total protein) was incubated with or without 50 000 units/ml N-Glycosidase F (PNGase F, New England Biolabs, USA) before immunoblotting as described above. For TPCN2 the manufacturers protocol was followed, i.e. protein was previously denatured at 100°C for 10 min and then incubated in PNGase F at 37°C for 60 min; for TPCN1, the denaturing step was omitted and PNGase F incubation carried out for 120 min.

Comparing PNGase F pre-treated and non-pretreated atrial protein by immunoblot revealed different protein bands for both TPCN1 and TPCN2. Thus TPCN1 and TPCN2 expressed endogenously in human myocardium was shown to be N-glycosylated. Glycosylation of TPCN1 corresponded with bands of molecular weights of 130 and 100 kDa which disappeared after PNGase F pre-treatment, while a more prominent band of 95 kDa appeared probably due to the protein running at a lower molecular weight after deglycosylation with PNGase F treatment (data not shown). Glycosylation of TPCN2 corresponded with two bands of molecular weights approximately 100 and 85 kDa; while a band of approximately 80 kDa appeared probably due to the

Table 2. Characteristics of control (CTL) group.

| Donor | Age | Gender | Cause of death | LVEF |
|-------|-----|--------|----------------|------|
| 1     | 16  | Female | RTA            | >50  |
| 2     | 58  | Male   | UNK            | >50  |
| 3     | 56  | Male   | RTA            | >50  |
| 4     | 56  | Male   | CVA            | >50  |
| 5     | 54  | Female | CVA            | >50  |
| 6     | 51  | Male   | UNK            | >50  |

CVA: cerebrovascular accident; LVEF: left ventricular ejection fraction (%; value assumed); UNK; data not available; RTA: road traffic accident.
protein running at a lower molecular weight after deglycosylation with PNGase F treatment (data not shown).

**Statistical Analyses**

We used a non-parametric approach because the patient population did not show a normal distribution for all demographic or clinical variables investigated (Shapiro-Wilk normality tests). For mRNA analysis, statistical significance of the differences between fold-changes in gene expression above baseline (2^ΔΔCt; hereafter referred to as gene expression levels) were tested using U Mann-Whitney, Kruskall-Wallis and post-hoc tests, for CTL, HF, ICM and DCM groups. For protein-level analysis, U Mann-Whitney or the Wilcoxon Sign Test was used. Significance was taken at p < 0.05 in all but post-hoc U Mann-Whitney tests where p < 0.016 was considered significant.

**Results**

**HF- and Aetiology-related Changes in Expression of Individual Genes of Fatty Acid Metabolism**

In HF (n = 36) as a whole, mRNA expression for CD36 (p = 0.006) and HFABP (p = 0.011) was found to be increased relative to CTL (Table 3 and Fig. 1). When considering CM-specific groups, mRNA expression of CD36 (p = 0.006) and HFABP (p = 0.003) was increased relative to CTL only in DCM (n = 20) but not in ICM (n = 16) (Table 3 and Fig. 1).

Analysis by western blot of the protein levels of CD36 confirmed that expression of this protein was significantly higher (p = 0.013, Mann-Whitney test) in the cardiac tissue of patients with HF of dilated aetiology (DCM; n = 7) than in those of ischaemic aetiology (ICM; n = 7) (Fig. 1).

HFABP protein levels analysis by western blot confirmed that the expression of this protein was significantly increased only in HF patients of dilated aetiology (n = 6 DCM vs n = 3 CTL, p = 0.031) (Fig. 1).

Finally, a direct comparison between ICM (n = 16) and DCM (n = 20) using post-hoc tests showed mRNA of the following three genes to be more highly expressed in DCM than ICM: PPARA (p = 0.015), PGCG1A (p = 0.010), CD36 (p = 0.012) (Table 3 and Figs. 1 and 2).

**CM-specific Correlations in Gene Expression (Table 4)**

Having found specific CM-dependent increases in expression of four genes (CD36, HFABP, PPARA and PGCG1A) involved in FA metabolism and HF-related increases in three Ca2^+^-handling genes (TPCN1, TPCN2 and IP3R1), we next compared gene expression levels by calculating Spearman correlation coefficients within CTL, ICM (n = 16) and DCM (n = 20) groups; any correlation with p < 0.05 in CTL and p < 0.01 in ICM and DCM was selected for further consideration. Of the 17 distinct gene pairs found to be correlated, 14 were positive (indicating that expression of both genes increased or decreased) and 3 were negative (indicating that expression of one gene increased while the other decreased) (Table 4).

**ICM (n = 16)**

There were 6 correlations among the genes that we studied, all of which had high 'r' values, indicating statistical reliability (Table 4). CD36 was correlated with PPARA (r = 0.74) and PGCG1A (r = 0.68), while PPARA was also correlated with PGCG1A (r = 0.63). Both CD36 and PPARA were correlated with TPCN1 (r = 0.67 and r = 0.78, respectively). TPCN2 was negatively correlated with CHOP (r = −0.66).

**DCM (n = 20)**

CD36 was correlated with PPARA, LCAD and PGCG1A (r = 0.93, r = 0.62, and r = 0.60 respectively), while PPARA was also correlated with LCAD and PGCG1A (r = 0.71 in each case). Finally, in this group CHOP showed its only positive correlation with the genes that we studied, with TPCN1 (r = 0.64). Thus, while we also found 6 correlations in this group which were distinct from

**Table 3.** Increases in myocardial gene expression in heart failure groups, according to cardiomyopathic aetiology.

| Gene         | Comparisons vs. CTL | ICM vs. DCM |
|--------------|---------------------|-------------|
| CD36        | p = 0.006 ns        | p = 0.006 p = 0.012 |
| HFABP       | p = 0.011 ns        | p = 0.003 p = 0.015 |
| PPARA       | ns                  | ns p = 0.015 |
| PGCG1A      | ns                  | ns p = 0.010 |
| TPCN1       | p = 0.018 ns        | p = 0.015 |
| TPCN2       | p = 0.001 p = 0.008 | p = 0.001 ns |
| IP3R1       | p = 0.035 ns        | ns ns       |

mRNA expression in heart failure (HF, n = 36) and aetiological groups of HF, compared with Control (CTL, n = 6) and directly between two groups: ICM (n = 16): ischaemic cardiomyopathy; DCM (n = 20): dilated cardiomyopathy. ns: not significant. doi:10.1371/journal.pone.0037505.t003

Fatty Acid and Calcium Metabolism in Failing Heart

In HF (n = 36) as a whole, mRNA expression for TPCN1 (p = 0.018), TPCN2 (p = 0.001) and IP3R1 (p = 0.035) was also increased relative to CTL (Table 3 and Figs. 1 and 2).

**HF- and Aetiology-related Changes in Expression of Ca2^+^-Handling Genes**

In HF (n = 36) as a whole, mRNA expression for TPCN1 (p = 0.018), TPCN2 (p = 0.001) and IP3R1 (p = 0.035) was also increased relative to CTL

In CM-specific groups, mRNA expression was increased relative to CTL (n = 6): in ICM (n = 16), TPCN2 (p = 0.008); in DCM (n = 20), TPCN1 (p = 0.015) and TPCN2 (p = 0.001). These results were confirmed at the protein level: TPCN1 expression was increased significantly (p = 0.002) in DCM (n = 13) relative to CTL (n = 4) and TPCN2 expression was increased significantly in ICM (n = 8; p = 0.016) and DCM (n = 6; p = 0.031) relative to CTL (n = 4) (Table 3 and Fig. 3).
those of CTL, three were common to and three distinct from ICM (Table 4).

Discussion

This study investigated HF-related alterations in ventricular myocardial expression of genes along the PPARA-PGC1A-HFABP-oxidation pathway. In human HF of DCM but not ICM aetiology we found significant increases in expression over CTL levels of genes regulating FA uptake (CD36/FAT) and intracellular transport (HFABP). The high levels of significance found at the RNA level together with confirmation at the protein level show that all the groups were statistically reliable. Furthermore, comparison of the two aetiological groups with each other showed that CD36, PPARA and PGC1A were all significantly more highly expressed in DCM than ICM. Interestingly, expression of all three genes was correlated in both DCM and ICM, but not in CTL.

As PPARA is an important regulator of HFABP and CPT1B, and PGC1A co-activates PPARA and regulates β-oxidation [6,12,13,23], our results suggest that there is a general up-regulation of the PPARA-PGC1A-HFABP-oxidation pathway in HF of DCM but not ICM aetiology. Our findings with PPARA are consistent with those of Schupp and colleagues [15] who found that LV myocardial expression of PPARA was increased at both mRNA and protein levels in 16 DCM patients compared with 15 CTL. In endomyocardial septal tissue from patients with HF of hypertrophic non-DCM aetiology no differences were found in PPARA mRNA expression; intriguingly, expression of the native protein was decreased but truncated protein increased in the same non-DCM group [16]. Although our tissue may have some different characteristics from those studied by Goikoetxea and colleagues [16], our results are in general agreement: compared with CTL, our non-DCM tissue did not show increased expression of PPARA either for mRNA or native protein; we did not study expression of the truncated form of the PPARA protein. The only
other report of altered PPARA expression in human HF has also shown mRNA to be unaffected, although native protein expression was decreased; however that study involved only five patients with apparently undefined HF aetiology [14].

Similar to our findings, Karamanlidis and colleagues have also recently reported that expression of neither PPARA nor PGC1A is altered at the mRNA level in failing left ventricular myocardium when HF taken as a whole [45]. Notably, that study did find a substantial increase in protein expression for PGC1A in the HF group as a whole (n = 23) over non-HF (n = 19), although it did not find differences in either mRNA or protein levels between the two CM groups that made up HF [ICM (n = 9) and non-ICM (n = 14)]. Other studies using human myocardium samples from different populations of end-stage heart failure patients have found increased [22,46] or decreased mRNA expression in HF for PGC1A [46,47]. Due to the variability that exist in the patient population between the different studies, differences in the therapies followed by the patients [some authors have proposed that angiotensin-converting enzyme inhibitors have a direct effect on cardiac remodelling and energy metabolism [48]] or in the clinical characteristics of the individuals [specially metabolic disorders such as diabetes; to note, we have selected for this study only non diabetic patients] could account in part for those controversial results.

Using experimental animal models of heart failure, other authors have reported unchanged or increased myocardial gene and/or protein expression levels of PGC1A and PPARA in rats [49,50]; however, these results, obtained in rodents in which heart failure was induced after three weeks of aortic banding or by feeding for 17 weeks with high salt diet, are hardly comparable with those obtained in human failing myocardium.

Due to the limited amount of human tissue available to us, we did not study protein expression for genes in which mRNA levels were unchanged (i.e. in HF as a whole). However, having found that PPARA mRNA levels were significantly greater in DCM than ICM, we confirmed that at the protein level. Thus, compared with Karamanlidis and colleagues [45], we have found an additional CM-related alteration in PPARA expression. Moreover, our CTL and DCM groups were more strictly defined than the respective non-HF and non-ICM groups used in that study [45]. It should also be noted that although our CTL group comprised 6 individuals, our data-set from them was statistically reliable, as shown by several highly significant alterations in expression between CTL and various HF groups, as well as the tight Spearman correlations obtained within the CTL group. The same series of patients and donors has, moreover, been used in recently published studies [51,52].

Our study did not show HF-related alterations in mRNA expression of either of the mitochondrial transport gene CPT1B or the β-oxidation gene LCAD, which are downstream of PPARA and PGC1A. This is in agreement with a previous study [45]. Other studies collectively show several discrepancies, with HF-related increases [18] or decreases in mRNA expression of CPT1B [46], and either unchanged mRNA [18] or decreased LCAD protein [20,22,46]. It should be noted that these studies have involved smaller numbers of patients of defined [22], non-defined [20], or mixed [18,46] HF aetiology.

Two previous studies have analyzed the expression of CD36 in human failing myocardium. Pohl et al. [53] found no differences in CD36 expression in the plasma membranes of cardiomyocytes in patients with dilated cardiomyopathy, whereas Uray et al. [54] showed a transcriptional upregulation of CD36 linked to reverse remodelling in end-stage heart failure patients. Ours is, however, the first report of CD36 expression being increased in human HF in the absence of diabetes mellitus, or analysed in terms of ICM or DCM, but our results, taken together with the data for PPARA, PGC1A and HFABP and previous reports of increased FA levels perturbing mitochondrial function [24,26–28] could make sense in one or more ways. In mouse myocardium, over-expression of PPARA has been shown to lead to over-expression of CD36 [55], and CD36 contains a PPARA-response element [56]. However, this effect might be indirect in cardiac [57,58] and skeletal muscle [59]. Thus, CD36 could have been up-regulated at the sarcolemma and therefore account in terms of FA transport for the increases we observed in those intracellular components of the FA metabolism pathway. Alternatively or as well, CD36 might have been up-regulated at the mitochondrial membrane. Due to the limited amount of tissue available, we could not carry out cellular

Figure 2. Different human myocardial expression of peroxisome-proliferator-activated-receptor-alpha (PPARA) between the two heart failure aetiological groups in absence of diabetes mellitus. i. box-plot of mRNA expression, showing a significant increase in DCM (n = 20) compared with ICM (n = 16, p = 0.015); ii. densitometry analysis of protein expression from immunoblots, showing a significant increase in DCM (n = 7) compared with ICM (n = 7, p = 0.006); iii. representative immunoblot for ii. (a.u.: arbitrary units).

doi:10.1371/journal.pone.0037505.g002
fractionation experiments to test these possibilities. Intriguingly, in a hypertrophic group of patients Heather and colleagues [60] have recently found a positive correlation between HFABP and CD36 at the protein level.

To summarise, this is the first time that CM-related diabetes mellitus independent differences have been reported in expression of genes involved in FA uptake, intracellular transport and oxidation in the same patients with failing human myocardium. It is notable that we also found potential alterations in the mutual regulation of some of these genes. Thus, in CTL CD36 was positively correlated with CPT1B, the principal mitochondrial membrane FA transporter, whereas in DCM it was correlated instead with the intra-mitochondrial β-oxidation enzyme LCAD. In ICM, by contrast, CD36 was correlated with neither of those mitochondrial factors but instead with the nuclear factors PPARA and PGC1A. HFABP was correlated only with PPARA and only in CTL. Taken together, these data suggest that regulation of CD36, HFABP and PPARA may differ not only in HF- but in CM-specific ways. On the other hand, there could also be alterations in gene regulation that are HF-related but not necessarily CM-specific, as seen by the positive correlations we

Figure 3. Increased human myocardial expression of Two-Pore Calcium channels TPCN1 and TPCN2 in heart failure as a whole (HF) and aetiological groups (ischaemic or dilated cardiomyopathy, ICM, DCM) and compared with non-diseased donors (CTL). A. Box-plot of TPCN1 and TPCN2 mRNA expression, showing for TPCN1 a significant increase over CTL (n = 6) for HF (n = 36, p = 0.018) and DCM (n = 20, p = 0.015); and for TPCN2 a significant increase over CTL (n = 6) for HF (n = 36, p = 0.001), ICM (n = 16, p = 0.008) and DCM (n = 20, p = 0.001). B. Densitometry analysis and representative immunoblot of TPCN1 protein expression showing a significant increase over CTL (n = 4) for DCM (n = 13, p = 0.002). C. Densitometry analysis and representative immunoblot of TPCN2 protein expression showing a significant increase over CTL (n = 4) for both ICM (n = 8, p = 0.016) and DCM (n = 6, p = 0.031). (a.u.: arbitrary units).

doi:10.1371/journal.pone.0037505.g003
found between CD36, PPARA and PGC1A in both DCM and ICM but not CTL.

We also found HF-related increases in expression of three genes involved in intracellular Ca\(^{2+}\) handling. Our increases in expression of IP\(_3\)R1 in HF as a whole are in agreement with those that have previously established increased IP\(_3\)R expression to be a general mechanism underlying changes in Ca\(^{2+}\)-signalling in heart disease [33]. Interestingly, we also found highly significant HF-related increases in gene expression of the novel endo-lysosomal Ca\(^{2+}\) channels TPCN1 and TPCN2, recently identified as endo-lysosomal Ca\(^{2+}\) channels and components of the receptor for NAADP, the most potent intracellular Ca\(^{2+}\) mobiliser known [38,39]. The up-regulation of both TPCN1 and TPCN2 that we found in HF could be related to the results of other studies showing increased expression of ryanodine receptors (RyR) in failing human myocardium [61,62]. TPCN2, moreover, had similar levels of significance in all HF groups that we analysed, regardless of CM, therefore suggesting for the first time that TPCN2 up-regulation could also be involved in a general mechanism underlying heart failure, at least with ICM and DCM aetiology.

![Figure 4. Increased human myocardial expression of Inositol-3-Phosphate Receptor sub-type 1 (IP\(_3\)R1) in heart failure as a whole (HF, \(n = 36\)). i. Box-plot of mRNA expression, showing a significant increase over CTL (\(n = 6, p = 0.035\)); ii. representative immunoblot for protein expression of IP\(_3\)R1. (a.u.: arbitrary units).

Table 4. Spearman correlations in myocardial gene expression, in control and cardiomyopathy groups.

| Gene   | CD36  | HFABP | CPT1B | LCAD  | PGC1A | IP3R1  | TPCN1  | CHOP  |
|--------|-------|-------|-------|-------|-------|--------|--------|-------|
| PPARA  | 0.74**(2) | 0.89*(1) | 0.71**(3) | 0.63** (2) | 0.83*(1) | 0.78** (2) | −0.83*(1) |
| CD36   | 0.93** (3) | 0.89*(1) | 0.62** (3) | 0.68** (2) | 0.67** (2) | |
| HFABP  | 0.89*(1) | 0.62** (3) | 0.89*(1) | 0.94** (1) | |
| IP3R1  | 0.71** (3) | 0.83*(1) | 0.71** (3) | −0.83*(1) | |
| TPCN1  | 0.64** (3) | 0.64** (3) | |
| TPCN2  | −0.66** (2) | |

Numerical values indicate strength (Spearman ‘r’) and asterisks level of significance (*p < 0.05, **p < 0.01) of correlations in expression between genes in three groups: control (1, \(n = 6\)); ischaemic cardiomyopathy (2, \(n = 16\)); dilated cardiomyopathy (3, \(n = 20\)). ‘r’ values were positive except for three correlations with CHOP.

doi:10.1371/journal.pone.0037505.t004
TPCN1 expression, on the other hand, while clearly increased in HF as a whole also tended towards a CM-difference. Thus, TPCN1’s increase in expression over CTL levels was statistically significant in DCM for both transcript and protein, whereas in ICM the transcript and the protein levels tended towards an increase that did not reach statistical significance. However, pertinent to a possible role in ICM, TPCN1 expression was correlated with that of CD36 and also of PPARα in ICM only. Indeed, those were the strongest (highest r values) and most significant HF-related correlations found between any Ca2+-handlers and any FA pathway gene in all HF groups that we studied (not all correlation data are shown). In contrast, in CTL, HFABP was strongly correlated with both IP₃R1 and TPCN1, and PPARα with IP₃R1.

The current data provide the first evidence that the endo-lysosomal system might be involved in cardiomyopathic alterations in Ca²⁺ signalling. It is already known that in failing myocardium IP₃R from the ER becomes more highly expressed at the junctional sarcoplasmic reticulum (SR) where RyR is located, causing RyR to become sensitized and increasing diastolic Ca²⁺ levels and other Ca²⁺ transients characteristic of human heart failure [36]. In other systems, the central role of lysosomes is now becoming recognised. TPCNs having been shown to trigger global Ca²⁺ release by recruiting Ca²⁺-induced Ca²⁺-release (CICR) at lysosomal-ER junctions and to regulate plasma membrane excitability by the targeting of Ca²⁺-release from sub-plasma membrane stores, thereby regulating plasma membrane Ca²⁺-activated channels [recently reviewed by Galione [63]]. Based on those studies and our current data, therefore, it may be hypothesised that in failing myocardium TPCN1 and/or TPCN2 are involved in altered distribution of Ca²⁺ to the SR and thereby to changes in membrane excitability that are known to occur in failing human heart [64].

Limitations of the Study

1) Due to the limited amount of human tissue available (and the relatively large number of genes we investigated) we could not carry out protein level expression analyses for all genes, comparisons in gene expression with glucose transporters, or functional studies. 2) The cardioplegic solution used in the transplant protocols to preserve the condition/function of the hearts can decrease cardiac energy metabolism.

Conclusions

In conclusion, using relatively large numbers of failing myocardial samples of ICM or DCM aetiology, we have found DCM-specific increases in expression of several important genes in the FA uptake and β-oxidation pathway. We have also found HF-related increases in expression of the novel endo-lysosomal Ca²⁺-handlers, TPCN1 and TPCN2; while TPCN2 was increased in all HF groups that we analysed, TPCN1 showed potential CM-specificity which merits further investigation. Finally, several of the genes investigated were found to be correlated, with patterns that differed between CTL and HF groups, suggesting HF- and CM-related alterations in the regulation of genes involved in FA and Ca²⁺ myocardial metabolism. We therefore propose that pharmacological modulation of FA metabolism in HF as advocated by Opie [1] and Lioneiti [2], among others, should be CM-specific in design, in particular for idiopathic DCM in which FA uptake and β-oxidation are increased with respect to ICM.

Acknowledgments

We thank the patients and donors for the myocardial tissue; Esther Roselló-Lleí and Raquel Cortés for administering the tissue samples and assistance with the clinical database; Lianne Davis and Ruth Tunn for affinity-purifying and testing the TPCN1 antibody; Martin Bootman and Elaine Brown with the clinical database; Carmen Cadarso and Isabel Martinez for statistical advice; and Charles Redwood and Emad Abu-Assi for critically reading the manuscript.

Author Contributions

Conceived and designed the experiments: FL, JRGJ MR MP JB JP MAB. Performed the experiments: VGR FL AM. Analyzed the data: FL MFO PVL DRP SFB TNM MC MB MAB. Contributed reagents/materials/analysis tools: TNM MC MB MP JRGJ FL AM. Presented reagents/materials/analysis tools: TNM MC MP MR JRGJ FL. Wrote the paper: FL PVL MC. N/A.

References

1. Opie LH, Knauti J (2011) The Adrenergic-Fatty Acid Load in Heart Failure. JACC 54: 1637–1646.
2. Lionetti V, Stanley WC, Recchia FA (2011) Modulating fatty acid oxidation in heart failure. Cardiovasc Res 98: 202–209.
3. van Blieu M, von Nieuwenhoven FA, van der Vusse GJ (2009) Metabolic remodelling of the failing heart: beneficial or detrimental? Cardiovasc Res 81: 420–428.
4. Glatz JF, Bonen A, Ouwers DM, Luiken JJ (2006) Regulation of sarcolemmal transport of substrates in the healthy and diseased heart. Cardiovasc Drugs Ther 20: 471–476.
5. Schwenk RW, Luiken JJ, Bonen A, Glatz JF (2008) Regulation of sarcolemmal glucose and fatty acid transporters in cardiac disease. Cardiovasc Res 79: 249–258.
6. Jawad JS, Keung W, Wang W, Ussher JR, Lopashuk GD (2011) Targeting fatty acid and carbohydrate oxidation – a novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta 1813: 1333–1350. pp 1333–1350.
7. Heathcr LG, Clarke K (2011) Metabolism, hypoxia and the diabetic heart. J Mol Cell Cardiol 50: 598–605.
8. Glatz JF, Bonen A, Luiken JJ (2008) Regulation of sarcolemmal glucose and fatty acid transporters in cardiac disease. Cardiovasc Res 79: 249–258.
9. van Blieu M, von Nieuwenhoven FA, van der Vusse GJ (2009) Metabolic remodelling of the failing heart: beneficial or detrimental? Cardiovasc Res 81: 420–428.
10. Schwenk RW, Luiken JJ, Bonen A, Glatz JF (2008) Regulation of sarcolemmal glucose and fatty acid transporters in cardiac disease. Cardiovasc Res 79: 249–258.
11. Jawad JS, Keung W, Wang W, Ussher JR, Lopashuk GD (2011) Targeting fatty acid and carbohydrate oxidation – a novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta 1813: 1333–1350. pp 1333–1350.
12. Desvergne B, Wahli W (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20: 649–681.
13. Duncan JG (2011) Peroxisome proliferator activated receptor-alpha (PPARα) and PPAR γ coactivator-1alpha (PGC-1α) regulation of cardiac metabolism. Circ Res 110: 1333–1350. pp 1333–1350.
14. Karbowska J, Kochan Z, Smolenski RT (2003) Peroxisome proliferator-activated receptor α is downregulated in the failing human heart. Cell Mol Life Sci 60: 49–53.
15. Schupp M, Künzler U, Fielitz J, Thomas J, Pregla R, et al. (2006) Cardiac PPARα expression in patients with dilated cardiomyopathy. Eur J Heart Fail 8: 290–294.
16. Goikoetxea MJ, Beaumont J, González A, López B, Querejeta R, et al. (2006) Altered cardiac expression of peroxisome proliferator-activated receptor-β/δ in patients with hypertensive heart disease. Cardiovasc Res 69: 899–907.
17. Holloway GP, Snook LA, Harris RJ, Glatz JF, Luiken JJ, et al. (2011) In obese Zucker rats, lipids accumulate in the heart despite normal mitochondrial content, morphology and long-chain fatty acid oxidation. J Physiol 585.1: 169–180.
18. Raegeli P, Young ME, Alcorn JI, Moravec CS, Frazier OH, et al. (2001) Metabolic gene expression in fetal and failing human heart. Circulation 104: 292–293.
19. Sharma V, DiAllo P, Parsons H, Allard MF, McNeill JH (2009) Metoprolol represses PGC1α-mediated carnitine palmitoyltransferase-1B expression in the diabetic heart. Eur J Pharmacol 607: 156–166.
20. Sack MN, Rader TA, Park S, Bastin J, McCune SA, et al. (1996) Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 94: 2837–2842.
21. Rennison JH, McElfresh TA, Okere IC, Patel HV, Foster AB, et al. (2008) Enhanced acyl-CoA dehydrogenase activity is associated with improved energy metabolism.
mitochondrial and contractile function in heart failure. Cardiovasc Res 79: 331–340.
22. Sihag S, Lib AY, Cresci S, Sucharov CC, Lehman J (2009) PGC-1α and ERRα target gene downregulation is a signature of the failing human heart. J Mol Cell Cardiol 47: 210–212.
23. Finck BN, Kelly JP (2007) Peroxisome proliferator-activated receptor γ coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease. Circulation 115: 2540–2548.
24. Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K (2004) Uncoupling proteins in the normal and failing heart. Physiol Rev 83: 1093–1129.
25. Wu P, Peters JM, Harris RA (2001) Adaptive increase in pyruvate dehydrogenase kinase 4 during starvation is mediated by peroxisome proliferator-activated receptor α dehydrogenase kinase expression by peroxisome proliferator-activated receptor α coactivator-1. J Biol Chem 276: 838–844.
26. Li Y, Wang Y, Li L, Peng S, Nie L, et al. (2009) Cardiac fatty acid metabolism in the normal and failing heart. PLoS ONE 4: e5772.
27. Finck BN, Kelly JP (2007) Peroxisome proliferator-activated receptor γ coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease. Circulation 115: 2540–2548.
28. Luciani DS, Gwiazda KS, Yang T-LB, Kalynyak TB, Bychkivska Y, et al. (2009) Phospholipase D couples the nuclear lamins to the Ca2+ release channels in the junctional sarcoplasmic reticulum. J Biol Chem 284: 33127–33136.
29. Finck BN, Clarke K (2004) Uncoupling proteins in the normal and failing heart. Physiol Rev 83: 1093–1129.
30. Fu S, Yang L, Li P, Hofmann O, Dicker L, et al. (2011) Aberrant lipid transporters and metabolic proteins mirror the metabolic shift in patients with dilated cardiomyopathy. Eur J Med Res 5: 438–442.
31. Kato T, Núñez S, Imamura K, Yasumoto T, Okada J, et al. (2010) Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ Heart Fail 3: 420–430.
32. Finck BN, Kelly JP (2004) Uncoupling proteins in the normal and failing heart. Physiol Rev 83: 1093–1129.
33. Maury JD, Narayan SM, Lalani GG, Trayanova NA (2009) Rate-dependent action potential alternans in human heart failure implicates abnormal intracellular calcium handling. Heart Rhythm 7: 1093–1101.
34. Minamino T, Komuro I, Kitaake M (2010) Endoplasmic reticulum stress as a therapeutic target in cardiovascular disease. Biochem Biophys Res Commun 387: 391–396.
35. Luciani DS, Gwiazda KS, Yang T-LB, Kalynyak TB, Bychkivska Y, et al. (2009) Roles of IP3R and RyR Ca2+ channels in endoplasmic reticulum stress and β-cell death. Diabetes 58: 422–432.
36. Luciani DS, Gwiazda KS, Yang T-LB, Kalynyak TB, Bychkivska Y, et al. (2009) Roles of IP3R and RyR Ca2+ channels in endoplasmic reticulum stress and β-cell death. Diabetes 58: 422–432.